4 results match your criteria: "University of Cambridge and Cambridge Genetics Knowledge Park[Affiliation]"
Recommendations in relation to the EU clinical trials directive and medical research involving incapacitated adults.
Wien Klin Wochenschr
April 2006
Faculty of Law, University of Cambridge and Cambridge Genetics Knowledge Park, UK.
Advances in genetic technology are increasing the availability of genetic tests, not only for rare single gene disorders, but also for common diseases such as breast and colo-rectal cancer. Before there can be widespread uptake of these tests, they must be evaluated to confirm the benefits of their use. But how should genetic tests be evaluated, given the speed at which new tests are emerging? One highly influential approach is the analytic validity, clinical validity, clinical utility and ethical, legal and social issues (ACCE) framework, which has provided a benchmark for the evaluation of genetic tests.
View Article and Find Full Text PDFCYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
Genet Med
February 2005
Department of Public Health and Primary Care, University of Cambridge and Cambridge Genetics Knowledge Park, Cambridge, UK.
Purpose: Two common variant alleles of the cytochrome CYP2C9 (CYP2C9*2 and CYP2C9*3) lead to reduced warfarin metabolism in vitro and in vivo. The study objective was to examine the strength and quality of existing evidence about CYP2C9 gene variants and clinical outcomes in warfarin-treated patients.
Methods: The study was a systematic review and meta-analysis.